Sinusitis-Pipeline Review, H1 2016

Sinusitis-Pipeline Review, H1 2016

  • Products Id :- GMDHC7746IDB
  • |
  • Pages: 80
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Sinusitis-Pipeline Review, H1 2016', provides an overview of the Sinusitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Sinusitis

The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects

The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Sinusitis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sinusitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Sinusitis Overview 7

Therapeutics Development 8

Pipeline Products for Sinusitis-Overview 8

Sinusitis-Therapeutics under Development by Companies 9

Sinusitis-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Sinusitis-Products under Development by Companies 13

Sinusitis-Companies Involved in Therapeutics Development 14

Amgen Inc. 14

F. Hoffmann-La Roche Ltd. 15

Knopp Biosciences LLC 16

Merck & Co., Inc. 17

Oticpharma Ltd 18

Paratek Pharmaceuticals, Inc. 19

Regeneron Pharmaceuticals, Inc. 20

Therabron Therapeutics, Inc. 21

Sinusitis-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

AMG-282-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

CG-201-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

dexpramipexole dihydrochloride-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

dupilumab-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

fluticasone propionate-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

omadacycline tosylate-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

omalizumab-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

P-008-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

PCL-1404-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Qi-117-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecule for Sinusitis-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Small Molecules for Chronic Rhinosinusitis-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

solithromycin-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Sinusitis-Recent Pipeline Updates 54

Sinusitis-Dormant Projects 75

Sinusitis-Product Development Milestones 76

Featured News & Press Releases 76

Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab 76

Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association 76

Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 77

Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 77

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Figures

Number of Products under Development for Sinusitis, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 12

Assessment by Monotherapy Products, H1 2016 22

Number of Products by Targets, H1 2016 23

Number of Products by Stage and Targets, H1 2016 23

Number of Products by Mechanism of Actions, H1 2016 25

Number of Products by Stage and Mechanism of Actions, H1 2016 25

Number of Products by Routes of Administration, H1 2016 27

Number of Products by Stage and Routes of Administration, H1 2016 27

Number of Products by Molecule Types, H1 2016 29

Number of Products by Stage and Molecule Types, H1 2016 29

List of Tables

Number of Products under Development for Sinusitis, H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Development, H1 2016 12

Products under Development by Companies, H1 2016 13

Sinusitis-Pipeline by Amgen Inc., H1 2016 14

Sinusitis-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 15

Sinusitis-Pipeline by Knopp Biosciences LLC, H1 2016 16

Sinusitis-Pipeline by Merck & Co., Inc., H1 2016 17

Sinusitis-Pipeline by Oticpharma Ltd, H1 2016 18

Sinusitis-Pipeline by Paratek Pharmaceuticals, Inc., H1 2016 19

Sinusitis-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 20

Sinusitis-Pipeline by Therabron Therapeutics, Inc., H1 2016 21

Assessment by Monotherapy Products, H1 2016 22

Number of Products by Stage and Target, H1 2016 24

Number of Products by Stage and Mechanism of Action, H1 2016 26

Number of Products by Stage and Route of Administration, H1 2016 28

Number of Products by Stage and Molecule Type, H1 2016 30

Sinusitis Therapeutics-Recent Pipeline Updates, H1 2016 54

Sinusitis-Dormant Projects, H1 2016 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Amgen Inc. F. Hoffmann-La Roche Ltd. Knopp Biosciences LLC Merck & Co., Inc. Oticpharma Ltd Paratek Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. Therabron Therapeutics, Inc.

Sinusitis Therapeutic Products under Development, Key Players in Sinusitis Therapeutics, Sinusitis Pipeline Overview, Sinusitis Pipeline, Sinusitis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143840
Site License
USD 4000 INR 287680
Corporate User License
USD 6000 INR 431520



I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]